Could a simple drug infusion stop a dangerous virus after stem cell transplants?
NCT ID NCT07703657
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This trial investigates whether giving two low doses of rituximab shortly after a stem cell transplant can prevent serious Epstein-Barr virus (EBV) infections. Participants are adults aged 16-65 who have received a donor stem cell transplant and are at medium-to-high risk for EBV reactivation. Half receive standard care plus rituximab infusions on days 21 and 28 after transplant, while the other half receive standard care alone. The study tracks EBV levels, complications, and survival for up to one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a low-dose infusion of rituximab, a drug that targets certain immune cells, given preventively after transplant
- What this could lead to
- If successful, this approach could reduce the risk of serious EBV-related complications after stem cell transplants, potentially improving survival and quality of life.
- What could go wrong
- This is a single-center trial with a moderate number of participants, so results may not apply broadly. Rituximab can cause infusion reactions and increase infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Study to reveal if younger donors boost transplant success
- Can donor t cells beat a tough virus after transplant? new trial aims to find out.
- Ancient heat therapy tested for Life-Threatening transplant complication
- Food bags for transplant patients: a recipe for better recovery?
- New hope for stubborn low platelets after transplant?
- Diabetes drug shows promise in preventing deadly transplant complication